Skip to main content
. 2018 Sep 7;9(70):33348–33359. doi: 10.18632/oncotarget.26072

Table 1. Top 20 identified genes for each Marker Cluster identified across HER2+, Luminal A/B and TNBC subtypes.

Marker Cluster 1
(Mosaic)
Marker Cluster 2
(High in TNBC)
Marker Cluster 3
(Luminal A/B)
Marker Cluster 4
(HER2+)
AR SOX10 PGR ERBB2
PIP ROPN1 ESR1 CEACAM5
CLC7A2 GABRP CCDC170 CEACAM6
ABCC8 VGLL1 GRPR ABCC11
F7 MSLN WNK4 NXPH1
BCAS1 CA9 CHAD ABCC12
CA12 GABBR2 AFF3 GRB7
BPIFB2 HORMAD1 GFRA1 PNMT
DHRS2 ZIC1 CPB1 MUCL1
TMC5 ART3 CLSTN2 LRRC26
ARG2 FABP7 PGLYRP2 UGT2B11
GATA3 A2ML1 KCNJ3 PP14571
SCGB2A2 FDCSP NEK10 DSCAM-AS1
LRRC31 PRAME GRIK3
MLPH KRT16 DNALI1
FOXA1 SBSN SERPINA6
HMGCS2 PPP1R14C SYT9
TTC6 CT83 NAT1
CYP4B1 NKX1-2 CST9
SYTL5 AGR3

The four Marker Clusters (and the putative group that they define) are provided with the top genes identified for each cluster with an FDR-adjusted p-value <0.01 and a log2 fold-change > 4 between the lowest and highest expressing subtypes. For clusters with more than 20 genes, only the top 20 are shown here. These genes correspond to those identified by hierarchical clustering in Figure 2.